UK markets closed

Celyad SA (CYAD)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
4.9800+0.0400 (+0.81%)
At close: 4:00PM EDT

Celyad SA

Axis Business Park
Rue Edouard Belin 2
Mont-Saint-Guibert 1435
Belgium
32 1 039 41 00
http://www.celyad.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees87

Key executives

NameTitlePayExercisedYear born
Mr. Michel E. J. Lussier BME, M.B.A., M.S., MBA, MS BMECo-Founder & Chairman81.37kN/A1956
Mr. Filippo Joseph PettiCEO, CFO & Director726.7kN/A1976
Dr. David Edward GilhamChief Scientific OfficerN/AN/A1965
Sara ZelkovicCommunications & Investor Relations DirectorN/AN/AN/A
Mr. Philippe DechampsChief Legal Officer & Corp. Sec.N/AN/A1970
Mr. Philippe NobelsChief HR Officer & VP of HRN/AN/A1966
Dr. Stephen Rubino M.B.A., Ph.D.Chief Bus. OfficerN/AN/A1958
Mr. Thomas LequertierHead of Cell Therapy Manufacturing UnitN/AN/AN/A
Dr. Charles Q. MorrisChief Medical OfficerN/AN/A1965
Dr. Frédéric LehmannVP of Clinical Devel. & Medical AffairsN/AN/A1964
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor-T (CAR-T) cell-based therapies for the treatment of cancer. Its lead product candidates includes CYAD-101, an allogeneic CAR-T candidate that is in Phase 1 clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, which is in Phase 1 clinical trial to treat relapsed / refractory multiple myeloma; and CYAD-02, an autologous CAR-T therapy that is in Phase 1 clinical trial for the treatment of hematological malignancies and solid tumors. The company's preclinical candidates, include allogeneic CAR-T candidate for the treatment of solid tumors; CYAD-221, shRNA based allogeneic CAR-T candidate to treat B-cell malignancies; and CYAD-231, a dual specific CAR-T candidate targeting natural killer group 2D ligands (NKG2D) and an undisclosed membrane protein. It has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and research and development collaboration, and license agreements with Horizon Discovery Group plc for the use of its shRNA technology to generate second non-gene-edited allogeneic platform. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.

Corporate governance

Celyad SA’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.